TCI-2026-E5C76E38Verified

NAD+ Longevity Formula

Acme Supplements · Analyzed January 6, 2026
72
Score
B
Grade

Score Breakdown

Evidence Strength
35%72
Dose Adequacy
30%68
Bioavailability
20%80
Safety Profile
15%90
Composite Score
72/100

Executive Summary

The NAD+ Longevity Formula demonstrates solid clinical backing with 22 validated studies across its key ingredients. The formulation features a robust 500mg dose of NAD+ that meets therapeutic thresholds established in clinical research, paired with resveratrol at clinically meaningful levels. Key Strengths: • NAD+ dose exceeds minimum effective dose (500mg vs 250mg threshold) • Strong safety profile with no severe interactions identified • All 22 citations verified with 94%+ fuzzy match accuracy Areas for Improvement: • Quercetin dose is below optimal range (250mg vs 500-1000mg recommended) • Consider adding bioavailability enhancers (piperine, phospholipids)

Ingredient Analysis

Product Dose
500mg
vs
Min Effective
250mg
Adequate

Supporting Studies (2)

Safety Warnings

Drug InteractionMODERATE

Resveratrol and quercetin may enhance anticoagulant effects.

warfarinaspirinclopidogrel

Claims Audit

ClaimStatusFTC Risk
Supports cellular energySUBSTANTIATEDLOW
Promotes healthy agingPARTIALLY SUBSTANTIATEDMODERATE
Reverses agingNOT SUBSTANTIATEDHIGH

Verification Status

PMIDs Validated22/22
Snippets Verified22/22
Hallucination CheckPASSED
Duration6m 52s

Validity Period

Expires
January 6, 2027

Embed Badge

Clinical Index
72
Verified
<script src="https://theclinicalindex.com/badge/TCI-2026-E5C76E38.js"></script>

Actions

FTC Compliance Report

Generated by The Clinical Index · January 6, 2026